Trial Profile
A Study to Evaluate the Frequency of Double Maintenance with Pemetrexed Plus Bevacizumab Discontinuation for Adverse Event and to Describe Main Toxicities Occurring During Double Maintenance in Patients with Non Small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 18 Dec 2015 New trial record